Ayahuasca para Ansiedad
Banisteriopsis caapi — 13 estudios científicos revisados
Preliminary¿Sirve Ayahuasca para ansiedad?
El método suele implicar la administración de una dosis estandarizada y el seguimiento de la respuesta emocional y cognitiva durante semanas, mostrando resultados prometedores en la reducción de...
Compuestos activos involucrados: harmina, harmalina, tetrahidroharmina, DMT (de Psychotria viridis), Alcaloides, Dimetiltriptamina, Flavonoides, Inhibido, Terpenos, Dopamina, Saponinas, Serotonina
Evidencia Científica
Los siguientes estudios han investigado la relación entre Ayahuasca y ansiedad:
Exploring Colombian medicinal flora used in indigenous and campesino health systems for neuropsychiatric disorders and neuropharmacological potential: an ethnopharmacological review.
Neuropsychiatric disorders affect nearly one billion people worldwide, yet many existing psychopharmacological treatments are limited by adverse effects, drug interactions, and variable efficacy. Ethnopharmacological knowledge embedded in Indigenous health systems offers important perspectives for understanding mental and neurological distress and for informing future research on central nervous system (CNS)-active plants. Colombia, one of the world's most biodiverse countries, harbors a rich medicinal flora that is deeply embedded in Indigenous and rural cultural practices. This review synthe
PubMed: 41890900Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.
Serotonergic psychedelics and 3,4-methylendioxtmethamphetamine (MDMA) are promising treatments for mental disorders with a continuously evolving evidence base. We searched Pubmed/Scopus/clinical trial registries up to 08july2025 for double-blind randomized controlled trials (RCTs) testing MDMA or serotonergic psychedelics in patients with mental disorders. Primary outcomes were change in disease-specific symptoms and all-cause discontinuation. Standardized mean differences (SMD) and relative risk (RR) were estimated using random-effects meta-analysis. Risk of bias (RoB) was assessed with Cochr
PubMed: 41205366N,N-dimethyltryptamine and Amazonian ayahuasca plant medicine.
OBJECTIVE: Reports have indicated possible uses of ayahuasca for the treatment of conditions including depression, addictions, post-traumatic stress disorder, anxiety and specific psychoneuroendocrine immune system pathologies. The article assesses potential ayahuasca and N,N-dimethyltryptamine (DMT) integration with contemporary healthcare. The review also seeks to provide a summary of selected literature regarding the mechanisms of action of DMT and ayahuasca; and assess to what extent the state of research can explain reports of unusual phenomenology. DESIGN: A narrative review. RESULTS: Co
PubMed: 35175662Ayahuasca reverses ischemic stroke-induced neuroinflammation and oxidative stress.
BACKGROUND: Ischemic stroke is a leading cause of death and disability worldwide. Survivors face disability and psychiatric sequelae resulting from ischemia-induced cell death and associated neuroinflammation, and oxidative stress. Herbal medicines have been shown to elicit neuroprotective effects following stroke due to their anti-inflammatory and antioxidant effects. Preliminary evidence suggests that Ayahuasca (AYA), a decoction made from the vine Banisteriopsis caapi containing β-carbolines and the shrub Psychotria viridis containing N, N-Dimethyltryptamine, might attenuate ischemia-induce
PubMed: 40043852Efficacy and Safety of Psychedelics in Mental Disorder Cases: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials.
Background: Psychedelic-assisted therapy is gaining renewed attention as a potential treatment for various mental disorders. Despite increasing numbers of randomized controlled trials (RCTs) and meta-analyses, a comprehensive synthesis of the evidence across different substances and indications is lacking. This umbrella review aims to evaluate the effectiveness and safety of psychedelic-assisted therapy-primarily psilocybin, MDMA, and LSD-across major psychiatric disorders, including depression, post-traumatic stress disorder (PTSD), and substance use disorders. Methods: We systematically iden
PubMed: 41517502Seguridad y Precauciones
El uso de la decocción de Banisteriopsis caapi conlleva riesgos fisiológicos y psicológicos significativos que requieren una comprensión profunda de su farmacodinamia. En el caso de mujeres en periodo de embarazo y lactancia, el uso está estrictamente contraindicado; la presencia de alcaloides beta-carbolinas (harmina, harmalina) puede interferir con el desarrollo fetal y no existen estudios que garanticen la ausencia de transferencia placentaria o lactancia segura. Para niños menores de 12 años, el uso es extremadamente peligroso debido a que su sistema nervioso central y su metabolismo hepático están en desarrollo, lo que aumenta el riesgo de neurotoxicidad y crisis hipertensivas. En cuanto a interacciones farmacológicas, la presencia de inhibidores de la monoamino oxidasa (IMAO) es crítica. La interacción con la warfarina (anticoagulante) es de alto riesgo, ya que los alcaloides pueden alterar la homeostasis sanguínea; la metformina puede verse afectada por cambios en el metabolismo glucémico inducidos por la planta; y los antihipertensivos pueden causar una crisis de hipertensión o hipotensión severa debido a la modulación de la presión arterial. Asimismo, el uso de antidepresivos de tipo ISRS (Inhibidores Selectivos de la Recaptación de Serotonina) puede desencadenar un síndrome serotoninérgico, una condición potencialmente mortal.
Otras plantas estudiadas para Ansiedad
Perfil completo: Ver todos los usos y evidencia de Ayahuasca →